Compare Grab Holdings Ltd. (GRAB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Novo Nordisk A/S — how do they compare? Grab Holdings Ltd. trades at $3.75 (market cap $15.62B), while Novo Nordisk A/S trades at $51.48 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 14.2× Grab Holdings Ltd.'s market cap, and Novo Nordisk A/S pays a 3.56% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | NVO | |
|---|---|---|
Market Cap | $15.62B | $222.24B |
Sector | Technology | Health |
52-Week High | $6.45 | $71.70 |
52-Week Low | $3.27 | $35.29 |
Enterprise Value | $11.32B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.80, down 3.55% today but showing strong fundamental improvement with revenue growth from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Technical indicators show a bullish overall signal with neutral oscillators. Recent news highlights CEO share sales and Uber CEO's board departure, creating mixed sentiment despite analyst optimism.
The outlook remains positive with 91.67% analyst buy ratings and a $5.45 consensus target offering 43% upside. Key risks include competitive pressures in Southeast Asia's ride-hailing market and volatile cash flow patterns, but sustained revenue growth and margin expansion support long-term potential.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
